Patent US10933073

Compositions and methods comprising a psilocybin derivative
[+] Show Details

US10933073

1. A dosage formulation comprising: (2) (2)

a purified psilocybin derivative selected from the group consisting of [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, and 4-hydroxy-N,N,N-trimethyltryptamine; and

a purified cannabinoid selected from the group consisting of Cannabichromene (CBC), Cannabichromenic acid (CBCA), Cannabichromevarin (CBCV), Cannabichromevarinic acid (CBCVA), Cannabidiol (CBD), Cannabidiolic acid (CBDA), Cannabidivarin (CBDV), Cannabidivarinic acid (CBDVA), Cannabigerol (CBG), Cannabigerolic acid (CBGA), Cannabigerovarin (CBGV), Cannabigerovarinic acid (CBGVA), Delta-9-tetrahydrocannabinol (THC), Delta-9-tetrahydrocannabinolic acid A (THCA-A), Delta-9-tetrahydrocannabinolic acid B (THCA-B), Delta-9-tetrahydrocannabivarin (THCV), Delta-9-tetrahydrocannabivarinic acid (THCVA).

2. A dosage composition of claim 1, wherein the purified cannabinoid is selected from the group consisting of Delta-9-tetrahydrocannabinol (THC), Cannabichromene (CBC), Cannabidiol (CBD), and Cannabigerol (CBG). (7) (0)

3. A dosage composition of claim 2 wherein the purified cannabinoid is Cannabichromene (CBC). (0)

8. A dosage composition of claim 2, wherein the purified psilocybin derivative is [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate. (0)

9. A dosage composition of claim 2, wherein the purified psilocybin derivative is 4-hydroxy-N-methyltryptamine. (0)

10. A dosage composition of claim 2, wherein the purified psilocybin derivative is [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate. (0)

11. A dosage composition of claim 2, wherein the purified psilocybin derivative is 4-hydroxytryptamine. (0)

12. A dosage composition of claim 2, wherein the purified psilocybin derivative is [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate. (0)

13. A dosage composition of claim 2, wherein the purified psilocybin derivative is 4-hydroxy-N,N,N-trimethyltryptamine. (0)

4. A dosage composition of claim 1, wherein molar ratio of the purified psilocybin derivative to the purified cannabinoid is about 100:1 to about 1:100. (1) (0)

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Patent US10933073

Compositions and methods comprising a psilocybin derivative

Patent Matrix® Search